Welcome to Avineuro Pharmaceuticals, Inc.

Avineuro Pharmaceuticals, Inc. reports positive Phase I clinical trial results on AVN-322, potent small molecule for treatment of Alzheimer’s disease.

admin — Mon, 01 Mar 2010 15:28:06 +0000

San Diego, CA – March 1st, 2010 - Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-322, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. AVN-322 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-322 in Alzheimer’s disease later this year.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:

Yan Lavrovsky, M.D., Ph.D.

CEO

Avineuro Pharmaceuticals, Inc.

6605 Nancy Ridge Drive

San Diego, CA 92121

Phone: (858) 436-1537

Fax: (858) 228-9798

E-mail: ylavrovsky@avineuro.com

www.avineuro.com

admin — Fri, 19 Feb 2010 22:20:16 +0000

07.10.2010 – 07.15.2010
Avineuro Pharmaceuticals, Inc. will be participating in Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 (ICAD)

http://www.alz.org/icad/overview.asp

Attendee: Yan Lavrovsky, ylavrovsky@avineuro.com

To schedule a meeting please contact us at info@avineuro.com

BIO-Europe Spring 2010

admin — Fri, 19 Feb 2010 22:16:18 +0000

03.08.2010 – 03.10.2010
Avineuro Pharmaceuticals, Inc. will be presenting at ABIO-Europe 2010 conference in Barcelona, Spain on Wednesday, March 10^th at 10.45 am

BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities.

Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE^®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

http://www.ebdgroup.com/bes/index.htm

Presenter: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.com

Avineuro Pharmaceuticals, Inc. announces beginning of Phase II clinical studies of AVN-101, potent small molecule for treatment of Alzheimer’s disease and anxiety.

admin — Tue, 02 Feb 2010 06:23:04 +0000

Avineuro Pharmaceuticals, Inc. announces beginning of Phase II clinical studies

San Diego, CA – February 1st, 2010 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-101, a potent multi-target small molecule for treatment of Alzheimer’s disease and anxiety. In Phase I studies AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. The compound demonstrated excellent exposure and half-life of more than 14 hours. Avineuro Pharmaceuticals, Inc. will present early clinical results with AVN-101at ICAD 2010 in July and an update on its entire CNS portfolio at Bio-Europe Spring 2010 in Barcelona in March.

About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Yan Lavrovsky, M.D., Ph.D.
CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 436-1537
Fax: (858) 228-9798
E-mail: ylavrovsky@avineuro.com
www.avineuro.com

ABIO-Europe 2009 conference in Vienna

admin — Mon, 02 Nov 2009 01:53:47 +0000

11.02.2009 – 11.04.2009
Avineuro Pharmaceuticals, Inc. participates in ABIO-Europe 2009 conference in Vienna on November 2-4, 2009

BIO-Europe is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry.

Attendees: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.com

Avineuro Pharmaceuticals, Inc. reports positive Phase I clinical trial results on AVN-101, potent small molecule for treatment of Alzheimer’s disease.

admin — Mon, 26 Oct 2009 23:33:52 +0000

San Diego, CA – October 26th, 2009 – Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-101, a potent small molecule for treatment of Alzheimer’s disease. AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 in Alzheimer’s disease in Q1 2010.

About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

BioNetwork West 2009 conference in Laguna Niguel

admin — Sat, 10 Oct 2009 01:57:29 +0000

Avineuro Pharmaceuticals, Inc. participates in BioNetwork West 2009 conference in Laguna Niguel, CA on October 5-7, 2009

BioNetwork offers the opportunity to meet with VPs of Business Development, Licensing, and Aliance Management from top companies offering their insights. Most importantly, BioNetwork provides a venue to meet potential partners and hold quality discussions – free of the distractions accompanying larger events. http://www.wbresearch.com/bionetworkwest/

Attendees: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.com

BioNetwork West 2009 conference in Laguna Niguel

admin — Mon, 05 Oct 2009 01:53:06 +0000

Avineuro Pharmaceuticals, Inc. participates in BioNetwork West 2009 conference in Laguna Niguel, CA on October 5-7, 2009

Attendees: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.co

Clinical Development Milestone Achieved for Avineuro CNS Collaboration.

admin — Fri, 02 Oct 2009 09:55:24 +0000

San Diego, CA – September 15, 2009

ChemDiv Inc. of San Diego CA and Avineuro Pharmaceuticals Inc. of San Diego CA announced successful milestones reached under ongoing research and development collaboration in area of neurodegenerative and psychiatric disorders. R&D services were provided by ChemDiv’s subsidiary Chemical Diversity Research Institute, based in Moscow, Russia. The existing agreement provides for research funding for developing clinical candidate compounds to obtain Proof of Concept in man. Avineuro is responsible for further clinical development and commercialization of drug candidates, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement.

In September 2008, ChemDiv entered into a collaboration agreement with Avineuro to develop multiple pre-clinical compounds for Alzheimer Disease and schizophrenia. Under the agreement ChemDiv provided pre-clinical development services to nominate additional backup leads and candidates for Avineuro. This collaboration led to the initiation of Phase I studies for two of the molecules in Avineuro’s pipeline, as well as successful completion of Phase I studies and initiation of Phase II studies for the third molecule in Avineuro’s pipeline.

About ChemDiv
ChemDiv Inc. (Chemical Diversity) is a global contract research organization accelerating external discovery and development of novel therapies through comprehensive Discovery outSource(TM) services, including discovery biology, medicinal and synthetic chemistry, and pre-clinical and clinical development.

About Avineuro Pharmaceuticals
Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry.

Contact:
Ronald Demuth, SVP & General Manager, ChemDiv, Inc.
6605 Nancy Ridge Drive, San Diego, CA 92121
Phone: (858) 794-4860
Fax: (858)794-4931
Email: rdemuth@chemdiv.com

Contact:
Yan Lavrovsky,CEO, Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com

Avineuro Pharmaceuticals, Inc. announces beginning of Phase II clinical studies of AVN-397, potent small molecule for treatment of anxiety and Alzheimer’s disease.

admin — Fri, 02 Oct 2009 09:46:14 +0000

Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

San Diego, CA – June 22nd, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of a two-armed, double-blinded, placebo- and a reference drug- controlled Phase II clinical studies of AVN-397, a potent small molecule for treatment of anxiety and Alzheimer’s disease. Avineuro Pharmaceuticals, Inc. will present at ICAD 2009 in Vienna, Austria in July.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com